ThirtyFiveBio is focused on the development of small molecule antagonists targeting the G protein-coupled receptor 35 (GPR35) to address serious digestive system disorders. The company leverages a deep understanding of GPR35 biology, which is implicated in various conditions such as inflammatory bowel diseases and digestive tract cancers. Their approach is guided by human genetics and proprietary bioinformatics, allowing them to identify and validate clinical opportunities for GPR35 antagonism. This strategy aims to provide a differentiated treatment option for patients with high unmet clinical needs, particularly in the context of digestive system metaplasia, dysplasia, and cancer.

The scientific foundation of ThirtyFiveBio's work includes the exploration of GPR35's role in epithelial growth programs that are upregulated in various digestive disorders. They have identified significant genetic associations and environmental factors that contribute to these conditions, including the impact of diet on GPR35 activation. Their research has led to the discovery of a novel endogenous agonist of GPR35 linked to high-fat diets, which is a risk factor for gut diseases. By utilizing advanced pharmacological techniques and genetic insights, ThirtyFiveBio aims to position GPR35 inhibitors as precision medicine agents tailored for specific patient subsets suffering from digestive system disorders.

United Kingdom

ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs.

Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35

ThirtyFiveBio

Company Details